Plain-English translation of NCT06459648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Researchers want to understand why some people with migraine respond well to anti-CGRP monoclonal antibodies—medications like Galcanezumab, Fremanezumab, Eptinezumab, and Erenumab—while others don't. This study will follow 350 patients over a year of treatment, collecting blood samples and brain imaging to identify early signs of who will benefit most from this medication.
These newer migraine medications work for many patients, but not everyone. By learning which patients respond best before they start treatment, doctors hope to prescribe this medication more precisely and help people avoid years of ineffective treatment.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic at the start of treatment, after 6 months, and after 12 months. At each visit, doctors will ask about your migraines and take blood samples. You'll also have a brain MRI scan before treatment begins. If your migraines improve and stay improved after treatment ends, you'll have one more follow-up visit 6 months later.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Spain